Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Clinical Trial
Questions What is the safety and efficacy of BIND-014, a docetaxel-containing nanoparticle targeting prostate-specific membrane antigen (PSMA), in metastatic castration-resistant prostate cancer, and does PSMA expression on circulating tumor cells decrease with treatment?
Findings In this phase 2 clinical trial of 42 chemotherapy-naive patients receiving BIND-014 therapy for metastatic castration-resistant prostate cancer, the median radiographic progression-free survival was 9.9 months. The most common adverse events were fatigue. nausea, and diarrhea.
Meaning Tumor cell death was associated with PSMA expression on circulating tumor cells, which, if validated, could serve as a pharmacodynamic response measure and help select patients with metastatic castration-resistant prostate cancer who are most likely to benefit from PSMA-directed treatment.